Breast tissue expansion device maker AirXpanders said yesterday that it filed for an initial public offering in Australia, looking to raise $36.5 million Australian (about $28 million U.S.).

Palo Alto, Calif.-based AirXpanders said it’s planning to float 73 million shares at A50¢ apiece.

AirXpanders’ AeroForm tissue expander is designed for use in post-mastectomy breast reconstructions to expand and stretch the skin and underlying muscle prior to a permanent breast implant, the company said.

“We believe that every woman deserves a comfortable, efficient breast reconstruction journey and the highest quality of life possible following a mastectomy, and that AeroForm is the best innovation in tissue expanders in decades. As a result, we consider that AeroForm provides an attractive and compelling new alternative for this important patient group in a significant market,” CEO Scott Dodson said in a press release.

AirXpanders’ tissue expander is approved for use in Europe and Australia, and the company is slated to present results form a pivotal trail of the device to the FDA for pre-market approval in mid-2015 with hopes of a 2016 market release in the U.S., it said.

“We are pleased to invite investors to share in AirXpanders’ exciting future as we scale up our manufacturing capacity and our sales and marketing infrastructure to undertake a full commercial launch of AeroForm in both Australia and the U.S.,” Dodson said.